Guillain-Barre Syndrome Drugs Market Report 2026

Guillain-Barre Syndrome Drugs Market Overview

• Guillain-Barre Syndrome Drugs market size has reached to $1.25 billion in 2025 • Expected to grow to $1.73 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Personalized Medicine Drives Guillain-Barre Syndrome Drugs Market Growth • Market Trend: Innovative Humanized Monoclonal Antibodies Revolutionize Guillain-Barre Syndrome Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Guillain-Barre Syndrome Drugs Market?

Guillain-Barre syndrome drugs refer to medications administered to manage the symptoms and complications of Guillain-Barre syndrome (GBS), an autoimmune disorder characterized by the immune system attacking the nervous system. These drugs are primarily aimed at modulating the peripheral immune system's activity to halt the progression of the disease and manage its symptoms. The main types of guillain-barre syndrome drug classes include immunoglobulins (IVIG), corticosteroids, and plasma exchange. Intravenous immunoglobulin (IVIG) is a medication made from pooled human blood plasma that contains a high concentration of antibodies. They are used in first-line treatment and adjunctive or supportive treatments and find several applications in clinics, hospitals, and others.

What Is The Guillain-Barre Syndrome Drugs Market Growth Forecast?

The guillain-barre syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $1.73 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising incidence of autoimmune neurological disorders, growing awareness of post-infectious gbs cases, increasing access to advanced hospital care, expansion of ivig manufacturing capacity, demand for rapid immune-modulating therapies in acute care. Major trends in the forecast period include continued reliance on intravenous immunoglobulin as first-line therapy, rising use of plasma exchange in severe guillain-barre cases, growing emphasis on early diagnosis and rapid treatment initiation, increasing demand for hospital-based intensive gbs management, steady use of supportive and adjunctive drug therapies.

Global Guillain-Barre Syndrome Drugs Market Segmentation

1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange 2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment 3) By Application: Clinic, Hospital, Other Applications Subsegments: 1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For GBS Treatment 2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone 3) By Plasma Exchange: Therapeutic Plasma Exchange (TPE), Plasmapheresis

What Are The Drivers Of The Guillain-Barre Syndrome Drugs Market?

The growing demand for personalized medicine is expected to propel the growth of the Guillain-Barré syndrome drugs market going forward. Personalized medicine refers to the customization of medical treatment based on an individual’s genetic makeup, biomarkers, or lifestyle factors to enhance therapeutic effectiveness and reduce adverse effects. The demand for personalized medicine is increasing due to advancements in genomics, rising disease complexity, improved diagnostic technologies, and strong regulatory support. The Guillain-Barré syndrome drugs market benefits from personalized medicine by enabling tailored treatment approaches that improve patient outcomes and reduce complications associated with generalized therapies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six therapies in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the Guillain-Barré syndrome drugs market. The increasing prevalence of autoimmune disorders is expected to propel the growth of the Guillain-Barré syndrome drugs market going forward. Autoimmune disorders refer to conditions in which the immune system mistakenly attacks the body's own healthy cells and tissues, leading to inflammation and tissue damage. The increasing prevalence of autoimmune disorders is primarily due to a genetic predisposition, meaning that individuals inherit certain genes that make their immune system more likely to mistakenly attack the body’s own tissues. Guillain-Barré syndrome drugs support autoimmune disorders by modulating the immune system to reduce abnormal antibody-mediated attacks on peripheral nerves, thereby alleviating symptoms and preventing disease progression. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the Guillain-Barré syndrome drugs market.

Key Players In The Global Guillain-Barre Syndrome Drugs Market

Major companies operating in the guillain-barre syndrome drugs market are CSL Behring LLC, Grifols SA, Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Kedrion Biopharma Inc., Alexion Pharmaceuticals Inc., Argenx SE, Annexon Inc., Hansa Medical AB, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Cadila Healthcare Limited, Akari Therapeutics Plc, Cellenkos Inc., Regenesance BV, Cresence AS

Global Guillain-Barre Syndrome Drugs Market Trends and Insights

Major companies operating in the Guillain-Barré syndrome (GBS) drugs market are focusing on developing innovative products such as humanized monoclonal antibodies to enhance therapeutic precision, reduce immune-mediated nerve damage, and strengthen their competitive position. A humanized monoclonal antibody refers to a laboratory-engineered antibody composed primarily of human antibody sequences with a small portion derived from mouse or rat monoclonal antibodies, designed to target specific immune components involved in GBS pathology and limit complement-mediated inflammation. For instance, in October 2023, Annexon Inc., a US-based clinical-stage biopharmaceutical company, announced that both the European Medicines Agency and the U.S. Food and Drug Administration had granted orphan drug designation to ANX005, a humanized monoclonal antibody that selectively inhibits C1q to prevent complement-driven neuronal injury in GBS. The company also reported completing target enrollment for its Phase 3 trial, with topline results expected in the first half of 2024, highlighting ANX005’s potential to rapidly halt autoimmune damage and support muscle strength recovery in affected patients.

Regional Insights

North America was the largest region in the guillain-barre syndrome drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Guillain-Barre Syndrome Drugs Market?

The guillain-barre syndrome drugs market consists of sales of monoclonal antibodies, cell therapies, and recombinant enzymes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Guillain-Barre Syndrome Drugs Market Report 2026?

The guillain-barre syndrome drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the guillain-barre syndrome drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.